SCHEMBL5098907

SCHEMBL5098907

N#Cc1ccc(O)c(-c2ccc3c(c2)OCO3)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCL2L1 Q07817 1/20 0.52
KDM1A O60341 1/20 0.50
MAOA P21397 1/20 0.50
XDH P47989 1/20 0.49
SLC22A12 Q96S37 1/20 0.49
MAPT P10636 3/20 0.49
ALOX15 P16050 2/20 0.49
HSD17B10 Q99714 2/20 0.49
HTT P42858 1/20 0.49
FNTA P49354 5/20 0.45
FNTB P49356 5/20 0.45
PGGT1B P53609 2/20 0.45
ALDH1A1 P00352 2/20 0.44
GSK3A P49840 2/20 0.44
GSK3B P49841 2/20 0.44
ADORA1 P30542 1/20 0.44
USP2 O75604 1/20 0.44
GAPDH P04406 1/20 0.44
ALOX5 P09917 1/20 0.44
KDM4E B2RXH2 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5091184 0.82 MAPT (0.49) MAPTALOX15HSD17B10HTTFNTA
SCHEMBL5098807 0.80 FNTA (0.51) MAPTALOX15HSD17B10HTTFNTA
SCHEMBL24909747 0.79 MEN1 (0.47) BCL2L1XDHSLC22A12MAPTALOX15
SCHEMBL30300332 0.79 MAPT (0.51) MAPTALOX15HSD17B10HTTALDH1A1
SCHEMBL140150 0.79 MAPT (0.51) MAPTALOX15HSD17B10HTTALDH1A1
SCHEMBL27579608 0.78 FNTA (0.49) MAPTALOX15HSD17B10HTTFNTA
SCHEMBL5099677 0.77 KDM1A (0.45) BCL2L1KDM1AMAOAXDHSLC22A12
SCHEMBL6572292 0.77 ALOX5 (0.47) BCL2L1MAPTALOX15HSD17B10HTT
SCHEMBL14919902 0.77 AR (0.51) BCL2L1MAPTALDH1A1GAPDHALOX5
SCHEMBL27579611 0.77 FNTA (0.47) MAPTALOX15HSD17B10HTTFNTA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7323570-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2008-01-29 US disclosed
US-7211595-B2 Farnesyltransferase inhibitors ABBOTT LABORATORIES (US) 2007-05-01 US disclosed
US-20060264476-A1 Farnesyltransferase Inhibitors ABBVIE INC. 2006-11-23 US disclosed
EP-1339695-B1 FARNESYLTRANSFERASE INHIBITORS ABBOTT LAB (US) 2006-04-19 EP disclosed
CN-1487924-A Farnesyl transferase inhibitors ���Ͽع����޹�˾ 2004-04-07 CN disclosed
US-20030087940-A1 Farnesyltransferase inhibitors ABBVIE INC. 2003-05-08 US disclosed
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents ABBOTT LABORATORIES 2002-08-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020115640-A1 Such as 4-(((6-chloro-2-(3-chlorophenyl)-3-pyridinyl) methoxy)(1-methyl-1H-imidazol-5-yl)methyl)benzonitrile; anticancer agents FNTB, FNTA, ACAT2 BCL2L1 1894/4885KDM1A 2069/4885MAOA 4228/4885
US-20060264476-A1 Farnesyltransferase Inhibitors FNTB, FNTA, FDPS BCL2L1 3484/4885KDM1A 4266/4885MAOA 2549/4885
US-20030087940-A1 Farnesyltransferase inhibitors FNTB, FNTA, FDPS BCL2L1 3028/4885KDM1A 3709/4885MAOA 2955/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.